An assessment by the Statin Liver Safety Task Force

2014 update

Harold Bays, David E. Cohen, Naga Chalasani, Stephen A. Harrison

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.

Original languageEnglish
JournalJournal of Clinical Lipidology
Volume8
Issue number3 SUPPL
DOIs
StatePublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Advisory Committees
Safety
Liver
Enzymes
Gastroenterology
United States Food and Drug Administration
Drug Interactions
Hepatitis
Autoimmune Diseases

Keywords

  • Cholesterol
  • Lipid
  • Liver
  • National Lipid Association
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

An assessment by the Statin Liver Safety Task Force : 2014 update. / Bays, Harold; Cohen, David E.; Chalasani, Naga; Harrison, Stephen A.

In: Journal of Clinical Lipidology, Vol. 8, No. 3 SUPPL, 2014.

Research output: Contribution to journalArticle

Bays, Harold ; Cohen, David E. ; Chalasani, Naga ; Harrison, Stephen A. / An assessment by the Statin Liver Safety Task Force : 2014 update. In: Journal of Clinical Lipidology. 2014 ; Vol. 8, No. 3 SUPPL.
@article{6b382ab4a26f42479a2df542f2d753d8,
title = "An assessment by the Statin Liver Safety Task Force: 2014 update",
abstract = "In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.",
keywords = "Cholesterol, Lipid, Liver, National Lipid Association, Statin",
author = "Harold Bays and Cohen, {David E.} and Naga Chalasani and Harrison, {Stephen A.}",
year = "2014",
doi = "10.1016/j.jacl.2014.02.011",
language = "English",
volume = "8",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "3 SUPPL",

}

TY - JOUR

T1 - An assessment by the Statin Liver Safety Task Force

T2 - 2014 update

AU - Bays, Harold

AU - Cohen, David E.

AU - Chalasani, Naga

AU - Harrison, Stephen A.

PY - 2014

Y1 - 2014

N2 - In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.

AB - In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.

KW - Cholesterol

KW - Lipid

KW - Liver

KW - National Lipid Association

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84899810207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899810207&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2014.02.011

DO - 10.1016/j.jacl.2014.02.011

M3 - Article

VL - 8

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 3 SUPPL

ER -